FDA's Abbreviated 510(k) Trades Data for Declarations of Conformity — Not for Less Testing

FDA's Abbreviated 510(k) Program guidance, finalized September 13, 2019 under Docket FDA-2019-D-4015, is the pathway device teams most often describe backwards. The common version: an Abbreviated 510(k) means less testing. The accurate version: it means less data in the submission — a declaration of conformity to a recognized standard, or a summary report against a special control, in place of the full study report FDA would otherwise have to work through. The predicate, the substantial-equivalence comparison, and the testing itself do not change.

Where the Abbreviated 510(k) came from

FDA created the Abbreviated 510(k) in March 1998, in the same document — The New 510(k) Paradigm — that introduced the Special 510(k). Both were originally framed as alternatives to the Traditional 510(k)'s full comparison-and-data submission, built around a shared idea: let the submitter demonstrate safety and effectiveness through something other than a complete data package when a faster, equally rigorous alternative already exists. For two decades the two pathways lived in one guidance document. In 2019, FDA split them into standalone final guidances — The Abbreviated 510(k) Program (FDA-2019-D-4015) and The Special 510(k) Program (FDA-2018-D-3304) — both dated September 13, 2019. The split clarified what had been getting conflated: Special 510(k) is about who is submitting and what changed (your own device, your own design-control record); Abbreviated 510(k) is about what already exists to evaluate the device type, regardless of who submits or whether it is a new device or a modification.

What actually gets abbreviated

A Traditional 510(k) answers the substantial-equivalence question with a full comparison table and the underlying performance data behind every point of difference from the predicate. An Abbreviated 510(k) answers the same question for a submitter who can point to one of three things already covering a given aspect of the device: an FDA-recognized consensus standard, a special control established for the device type, or a device-specific guidance document. Where one of those applies, the submitter provides a declaration of conformity to the standard, or a summary report describing how the special control or guidance document was used — not the raw study data FDA would otherwise have to review line by line. That is the entire mechanic. It is a data-presentation shortcut built on method, not a reduction in what safety and effectiveness the device actually has to demonstrate.

• Declaration of conformity. A signed statement that the device meets an FDA-recognized consensus standard in full, without deviation — FDA can still ask for the test report behind it.
• Summary report. For a special control or guidance document: how it was used during development and testing, how it addressed the specific risk it targets, and the manufacturer's efforts to conform — a citation alone does not satisfy this.
• The predicate comparison. Unchanged. Intended use and technological characteristics are still argued exactly as in a Traditional 510(k)'s predicate selection.
• The 510(k) Summary or Statement. Still required under 21 CFR 807.92 or 807.93, the same as any 510(k) type.

Less data to review is not the same claim as less evidence required. FDA is still testing the device against the standard — it is simply trusting the standard's own test method to have already answered the question. Why the eligibility call matters more than the paperwork

The eligibility call teams get wrong

The failure mode is not choosing Abbreviated when Traditional was required — FDA simply reviews what was submitted and asks for more where coverage is thin. The failure mode is treating the pathway as a reason to under-document: assuming a standard applies without confirming FDA still recognizes the current edition, or writing a summary report that names a special control without showing how it was applied to this device's specific risk. FDA's recognized consensus standards list changes; a standard cited by an earlier clearance can be withdrawn or superseded by the time a new submission relies on it. A Pre-Submission that confirms current recognition status and the acceptable scope of a declaration of conformity is cheap relative to an Additional Information request discovered mid-review. The device's 510(k) clearance strategy should settle this before the testing plan is built, not after.

A related, newer expansion is worth knowing even though it is a separate mechanic: FDA's Safety and Performance-Based Pathway, finalized the same week in September 2019, lets a submitter compare a device to FDA-identified performance criteria rather than to a specific predicate's own raw data, for device types where FDA has published those criteria. It still requires a predicate and still sits inside the Abbreviated concept's broader logic — trust an established reference instead of re-proving the question from scratch — but it is a distinct, narrower guidance (FDA-2018-D-1387), not a synonym for the Abbreviated 510(k) Program itself. Conflating the two is a smaller version of the same mistake that conflates Abbreviated with Special: assuming the fastest-sounding option is the one that applies without checking which guidance actually covers the device.